Cadrenal Therapeutics to Seek FDA Rare Pediatric Designation
Ponte Vedra, Florida | June 18, 2026 Cadrenal Therapeutics, Inc. announced plans to submit a request to the U.S....
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
Ponte Vedra, Florida | June 18, 2026 Cadrenal Therapeutics, Inc. announced plans to submit a request to the U.S....
MIAMI, Florida, United States – May 10, 2026 Longeveron announced details from a constructive Type C meeting with the...
PRINCETON, N.J., USA, March 29, 2026 Bristol Myers Squibb has announced positive Phase 3 results from the SCOUT-HCM trial...
February 24, 2026 – Cincinnati, Ohio & Tacoma, Washington, USA Cincinnati Children’s Hospital Medical Center has announced a strategic...
Abbott Park, Illinois, December 18, 2025 — Abbott has secured U.S. Food and Drug Administration (FDA) clearance and CE...
